Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis

References

• Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18(7):493–12. PMID: 34002083. doi:10.1038/s41575-021-00457-x.
   PubMed Web of Science ®Google Scholar
• Chen X, Yi B, Liu Z, Zou H, Zhou J, Zhang Z, Xiong L, Wen Y. Global, regional and national burden of pancreatic cancer, 1990 to 2017: results from the global burden of disease study 2017. Pancreatology. 2020;20(3):462–9. PMID: 32113937. doi: 10.1016/j.pan.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Collaborators GBD Pancreatic Cancer. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2019;4(12):934–47. PMID: 32061329. doi:10.1016/S2468-1253(20)30018-2.
   PubMed Web of Science ®Google Scholar
• Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018;4(6):418–28. PMID: 29860986. doi:10.1016/j.trecan.2018.04.001.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. PMID: 31940268. doi:10.1016/j.immuni.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11(1):24–37. PMID: 24247168. doi:10.1038/nrclinonc.2013.208.
   PubMed Web of Science ®Google Scholar
• Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309–37. PMID: 34624224. doi: 10.1016/j.cell.2021.09.020.
   PubMed Web of Science ®Google Scholar
• Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38. PMID: 20585380. doi:10.1007/s11192-009-0146-3.
   PubMed Web of Science ®Google Scholar
• Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(Suppl 1):5303–10. PMID: 14724295. doi:10.1073/pnas.0307513100.
   PubMed Web of Science ®Google Scholar
• Ren D, Lee B, Brehmer M. Charticulator: interactive construction of bespoke chart layouts. IEEE Trans Vis Comput Graph. 2019;25(1):789–799. PMID: 30136992. doi:10.1109/TVCG.2018.2865158.
   Web of Science ®Google Scholar
• Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509–28. PMID: 34937915. doi:10.1038/s41573-021-00345-8.
   PubMed Web of Science ®Google Scholar
• Association Pancreatic Cancer Committee of Chinese Anticancer. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2020 version). Zhonghua Wai Ke Za Zhi. 2021;59(2):81–100. PMID: 33378799. doi:10.3760/cma.j.cn112139-20201113-00794.
   PubMedGoogle Scholar
• Smith DR. Bibliometrics, dermatology and contact dermatitis. Contact Dermatitis. 2008;59(3):133–6. PMID: 18759892. doi:10.1111/j.1600-0536.2008.01405.x.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66. PMID: 31350295. doi:10.1158/0008-5472.CAN-18-3962.
   PubMed Web of Science ®Google Scholar
• Wang S, Li Y, Xing C, Ding C, Zhang H, Chen L, You L, Dai M, Zhao Y. Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer. Am J Cancer Res. 2020;10(7):1937–53. PMID: 32774994.
   PubMed Web of Science ®Google Scholar
• Jang JE, Hajdu CH, Liot C, Miller G, Dustin ML, Bar-Sagi D. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 2017;20(3):558–71. PMID: 28723561. doi: 10.1016/j.celrep.2017.06.062.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med. 2016;8(367):367ra166. PMID: 27903862. doi:10.1126/scitranslmed.aag3187.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int J Cancer. 2011;128(4):897–907. PMID: 20473889. doi:10.1002/ijc.25399.
   PubMed Web of Science ®Google Scholar
• Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015;6(40):43005–15. PMID: 26515728. doi: 10.18632/oncotarget.5656.
   PubMedGoogle Scholar
• Ohl K, Tenbrock K. Reactive oxygen species as regulators of MDSC-mediated immune suppression. Front Immunol. 2018;9:2499. PMID: 30425715. doi:10.3389/fimmu.2018.02499.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74. PMID: 19197294. doi:10.1038/nri2506.
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen S-H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66(2):1123–31. PMID: 16424049. doi: 10.1158/0008-5472.CAN-05-1299.
   PubMed Web of Science ®Google Scholar
• Denardo DG, Galkin A, Dupont J, Zhou L, Bendell J. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. J Immunother Cancer. 2021;9(8):e003005. PMID: 34452928. doi: 10.1136/jitc-2021-003005.
   PubMed Web of Science ®Google Scholar
• Kuang DM, Zhao Q, Peng C, Xu J, Zhang J-P, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–37. PMID: 19451266. doi: 10.1084/jem.20082173.
   PubMed Web of Science ®Google Scholar
• Lu SW, Pan HC, Hsu YH, Chang K-C, Wu L-W, Chen W-Y, Chang M-S. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models. Nat Commun. 2020;11(1):4611. PMID: 32929072. doi: 10.1038/s41467-020-18244-8.
   PubMed Web of Science ®Google Scholar
• Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discovery. 2016;6(8):870–85. PMID: 27179037. doi:10.1158/2159-8290.CD-15-134.
   PubMed Web of Science ®Google Scholar
• Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. PMID: 32393771. doi:10.1038/s41575-020-0300-1.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212–7. PMID: 24277834. doi:10.1073/pnas.1320318110.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–60. PMID: 27376576. doi:10.1038/nm.4123.
   PubMed Web of Science ®Google Scholar
• Symeonides SN, Anderton SM, Serrels A. FAK-inhibition opens the door to checkpoint immunotherapy in pancreatic cancer. J Immunother Cancer. 2017;5(1):17. PMID: 28239470. doi: 10.1186/s40425-017-0217-6.
   PubMedGoogle Scholar
• Tang D, Yuan Z, Xue X, Lu Z, Zhang Y, Wang H, Chen M, An Y, Wei J, Zhu Y, et al. High expression of galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer. 2012;130(10):2337–48. PMID: 21780106. doi:10.1002/ijc.26290.
   PubMed Web of Science ®Google Scholar
• Kesh K, Garrido VT, Dosch A, Durden B, Gupta VK, Sharma NS, Lyle M, Nagathihalli N, Merchant N, Saluja A, et al. Stroma secreted IL6 selects for “stem-like” population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways. Cell Death Dis. 2020;11(11):967. PMID: 33177492. doi:10.1038/s41419-020-03168-4.
   PubMed Web of Science ®Google Scholar
• Nezhad Shamohammadi F, Yazdanifar M, Oraei M, Kazemi MH, Roohi A, Mahya Shariat Razavi S, Rezaei F, Parvizpour F, Karamlou Y, Namdari H, et al. Controversial role of γδ T cells in pancreatic cancer. Int Immunopharmacol. 2022;108:108895. PMID: 35729831. doi:10.1016/j.intimp.2022.108895.
   PubMed Web of Science ®Google Scholar
• Chabab G, Boissière-Michot F, Mollevi C, Ramos J, Lopez-Crapez E, Colombo P-E, Jacot W, Bonnefoy N, Lafont V. Diversity of tumor-infiltrating, γδ T-cell abundance in solid cancers. Cells. 2020;9(6):1537. PMID: 32599843. doi: 10.3390/cells9061537.
   PubMed Web of Science ®Google Scholar
• Seifert AM, List J, Heiduk M, Decker R, von Renesse J, Meinecke A-C, Aust DE, Welsch T, Weitz J, Seifert L. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2020;146(12):3233–40. PMID: 32865617. doi: 10.1007/s00432-020-03367-8.
   PubMed Web of Science ®Google Scholar
• Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK, et al. γδ T cells support pancreatic oncogenesis by restraining αβ T cell activation [published correction appears in cell. 2020 Nov 12;183(4): 1134-1136]. Cell. 2016;166(6):1485–1499.e15. PMID: 27569912. doi:10.1016/j.cell.2016.07.046.
   PubMed Web of Science ®Google Scholar
• Bejarano L, Jordao MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933–59. PMID: 3381112. doi:10.1158/2159-8290.CD-20-1808.
   PubMed Web of Science ®Google Scholar
• Ho WJ, Jaffee EM. Macrophage-targeting by CSF1/1R blockade in pancreatic cancers. Cancer Res. 2021;81(24):6071–3. PMID: 34911778. doi:10.1158/0008-5472.CAN-21-3603.
   PubMed Web of Science ®Google Scholar
• Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. JCI Insight. 2018;3(13). PMID: 29997287. doi:10.1172/jci.insight.122092.
   Web of Science ®Google Scholar
• Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, et al. Results from a phase IIb, randomized, multicenter study of GVAX Pancreas and CRS-207 compared with chemotherapy in adults with Previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019;25(18):5493–502. PMID: 31126960. doi:10.1158/1078-0432.CCR-18-2992.
   PubMed Web of Science ®Google Scholar
• Padoan A, Plebani M, Basso D. Inflammation and pancreatic cancer: focus on metabolism, cytokines, and immunity. Int J Mol Sci. 2019;20(3):676. PMID: 30764482. doi: 10.3390/ijms20030676.
   PubMed Web of Science ®Google Scholar
• Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, et al. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA -A24-positive pancreatic adenocarcinoma. Cancer Sci. 2019;110(8):2378–85. PMID: 31218770. doi:10.1111/cas.14106.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother. 2013;62(5):949–54. PMID: 23589109. doi: 10.1007/s00262-013-1427-5.
   PubMed Web of Science ®Google Scholar
• Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, et al. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J Immunother Cancer. 2020;8(2):e000772. PMID: 32690771. doi:10.1136/jitc-2020-000772.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. PMID: 29567707. doi: 10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Ali AI, Oliver AJ, Samiei T, Chan JD, Kershaw MH, Slaney CY. Genetic redirection of T cells for the treatment of pancreatic cancer. Front Oncol. 2019;9:56. PMID: 30809507. doi:10.3389/fonc.2019.00056.
   PubMed Web of Science ®Google Scholar
• Bear AS, Vonderheide RH, O’Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788–802. PMID: 32946773. doi:10.1016/j.ccell.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17(5):651–62. PMID: 27055731. doi:10.1016/S1470-2045(16)00078-4.
   PubMed Web of Science ®Google Scholar
• Linehan D, Noel MS, Hezel AF, Wang-Gillam A, Eskens F, Sleijfer S, Desar IME, Erdkamp F, Wilmink J, Diehl J, et al. Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: correlation with blood monocyte counts. J Clin Oncol. 2018;36(5_suppl):92–. doi:10.1200/JCO.2018.36.5_suppl.92.
   Web of Science ®Google Scholar
• Li M, Li M, Yang Y, Liu Y, Xie H, Yu Q, Tian L, Tang X, Ren K, Li J, et al. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy. J Control Release. 2020;321:23–35. PMID: 32035193. doi:10.1016/j.jconrel.2020.02.011.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–42. PMID: 32266087.
   PubMed Web of Science ®Google Scholar
• O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22(1):118–31. PMID: 33387490. doi:10.1016/S1470-2045(20)30532-5.
   PubMed Web of Science ®Google Scholar
• Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, Golan T, Geva R, Borad MJ, Pedersen KS, et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020;26(6):878–85. PMID: 32451495. doi:10.1038/s41591-020-0880-x.
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255. PMID: 31196207. doi:10.1186/s13046-019-1259-z.
   PubMed Web of Science ®Google Scholar
• Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, et al. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets. 2021;25(11):987–1005. PMID: 34806517. doi:10.1080/14728222.2021.2010044.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100–5. PMID: 32376951. doi:10.1038/s41586-020-2229-5.
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang S-C, Vlahovic G, et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5(10):1431–8. PMID: 31318392. doi:10.1001/jamaoncol.2019.1588.
   PubMed Web of Science ®Google Scholar
• TTB H, Nasti A, Seki A, Komura T, Inui H, Kozaka T, Kitamura Y, Shiba K, Yamashita T, Yamashita T, et al. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis. J Immunother Cancer. 2020;8(2):e001367. PMID: 33188035. doi:10.1136/jitc-2020-001367.
   PubMed Web of Science ®Google Scholar